Q: Was D-Box dropped from the growth portfolio as a result of a specific event or news release? I.e., why not wait for the next earnings release to make a decision?
Q: I would like to know how I can unprotect the Excel file on the model portfolio. Some cells appear with #### because the number is exceeding the width of the column. I would need the protection password for the file please.
Thank you
Jean
Q: Hi 5i,
Just wondering if you knew how PKI's share offering was moving along? Do you know if it was well received, or was it under subscribed? I'm wondering if the share price will drop after the closing date and if I could get a better price on it.
Q: I have emulated the Balanced Equity portfolio as much as possible but the proportions don't max exactly. PBH and KXS are not yet at the 6% level (close) so I did not re-balance. Trust this in line with your thinking.
BTW...April numbers in my three trading accounts are: +1.54, +3.1 and +2.14. And my TFSA, begun in January, 2015, is almost doubled. Thanks for your genius. I tend to think of all three accounts as a single portfolio but iTrade can't combine them.
Q: In a response to SIS' recent acquisition, you noted it was "30% accretive to financial metrics". I've seen a similar term used in other responses regarding acquisitions. What exactly does this mean, and what amount of "accretion" is considered good in an acquisition? Thanks
Q: Your Q&A refers to potential dividend and cash flow concerns raised by short sellers. I cannot find any discussion of this issue in your notes so I wonder if you could follow up and indicate whether these concerns have any merit and if so what basis they have. The price is down to a level which otherwise could be an attractive entry point. Thank you.
Q: I have owned HCG since 2000.This is a stock I thought I may never sell, but due to circumstances I have considered selling especially after your advise to get out. At what price would you sell as the stock can go up or down 15% in a day? I do not think putting a market price would by wise. I was considering selling at $8.00 per share but the next day the shares were down to about $6.75. Today they are trading at $7.75.
Q: David Taylor was interviewed in the Globe and Mail today. He feels there is value in HCG. His optimism rests on the book value of the company, which he estimates is between $15 and $28 a share. Do you feel this is a reasonable estimate of book value? If so could there be a significant opportunity for brave and patient investors?
Q: Would you recommend investing in this preferred at this time (given the drop in its price recently), and would you consider the preferred as a safer investment vs investing in the common shares. The reset is Canada 5 year bond yield + 4.78% (September 30, 2019). I am not sure, but are there any more Canada bonds to be issued going forward? If not how will the rate be set in the absence of further Canada bonds being issued..
I slowly building a US portfolio and already own (DIS, MKSI, and JPM.) What other names would you suggest for the remaining sectors? Mostly looking for long terms growth.
Q: I've been interested in NXO lately due to the market activity so I did a bit of research on the technology itself. The theory of flat lenses and the proof of concept that it works was discovered by Federico Capasso and his team at Harvard University. When their research paper was first published, Federico Capasso was contacted by one of the world's largest smartphone manufactures (which means they are now working on it). Since then many of the research team members have been picked off by various universities and companies world wide to develop it's potential further.
The point is (NXO) Nexoptic did not invent the technology of their prototype lens system.
So investors beware that NXO really has nothing proprietary, nor do they have the size and scale of potential competitors. The idea that an iPhone will someday have Nexoptic lenses is probably a bit of a stretch. The best outcome I see is that their telescope patent (if approved) is sold to a larger manufacturer, which is not going to make the average investor any money over the next 5 years.
I hope I'm wrong and wish them luck!
Q: Over the last 2 years, I lost quite a lot of money investing in a promotional companies, or, companies with growth profiles too good to be true. On the other hand, I always made money investing in a company that meets all the following criterias: (1) boring (2) sells products I use (3) existed for 5 years (4) pays a dividend under 4%. Jean-Coutu meets passes this test so I'm considering it my father's portfolio. Is there something *not* to like about it? How about the latest news on the government meddling with drug generics pricing. This this take a positive turn? Thank you!